Please use this identifier to cite or link to this item:
Authors: de Oliveira Dias, Joao Rafael [UNIFESP]
de Andrade, Gabriel Costa [UNIFESP]
Kniggendorf, Vinicius Ferreira [UNIFESP]
Novais, Eduardo Amorim [UNIFESP]
Maia, Andre [UNIFESP]
Meyer, Carsten [UNIFESP]
Watanabe, Sung Eun Song [UNIFESP]
Farah, Michel Eid [UNIFESP]
Rodrigues, Eduardo Buschele [UNIFESP]
Keywords: ziv-aflibercept
age-related macular degeneration
full-field electroretinography
multifocal electroretinography
Issue Date: 2017
Publisher: Lippincott Williams & Wilkins
Citation: Retina-The Journal Of Retinal And Vitreous Diseases. Philadelphia, v. 37, n. 8, p. 1499-1507, 2017.
Abstract: Purpose: To evaluate the 6-month safety and efficacy of ziv-aflibercept intravitreal injections for treating exudative age-related macular degeneration. Methods: Fifteen patients with unilateral exudative age-related macular degeneration were enrolled. The best-corrected visual acuity was measured and spectral domain optical coherence tomography was performed at baseline and monthly. Full-field electroretinography and multifocal electroretinography were obtained at baseline and 4, 13, and 26 weeks after the first injection. All patients received three monthly intravitreal injections of ziv-aflibercept (1.25 mg) followed by as-needed treatment. Results: Between baseline and 26 weeks, the mean logMAR best-corrected visual acuity improved (P = 0.00408) from 0.93 +/- 0.4 (20/200) to 0.82 +/- 0.5 (20/160) logarithm of the minimum angle of resolution, respectively
the central retinal thickness decreased significantly (P = 0.0007) from 490.3 +/- 155.1 microns to 327.9 +/- 101.5 microns
the mean total macular volume decreased significantly (P < 0.0001) from 9.51 +/- 1.36 mm(3) to 8.08 +/- 1.34 mm(3), and the a-wave implicit time increased, with no differences in the other full-field electroretinography parameters. The average multifocal electroretinography macular responses within the first central 15 degrees showed significantly (P < 0.05) increased P-1 amplitudes at 26 weeks. No systemic or ocular complications developed. Conclusion: Intravitreal ziv-aflibercept significantly improved the best-corrected visual acuity, multifocal electroretinography amplitudes, central retinal thickness, and total macular volume from baseline to 26 weeks. No retinal toxicity on full-field electroretinography or adverse events occurred during the follow-up period.
ISSN: 0275-004X
Other Identifiers:
Appears in Collections:Artigo

Files in This Item:
File SizeFormat 
WOS000406108700010.pdf420.83 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.